We redesigned FDA-TRACK! It has been a little over one year since the launch of the FDA-TRACK website. After collecting web traffic data during this time, we decided to make some changes to the dashboard pages in hopes of improving your experience. The changes include:
- Cleaner look-and-feel;
- Charts and options to overlay related measures;
- XML downloads; and
- “FDA-TRACK Indices” by program area, for easier access navigation to specific content.
Check out these before and after shots:
Please visit any of the FDA-TRACK dashboard pages to see these changes.
In June, I had the opportunity to lead a delegation of food safety officials from the Food and Drug Administration to meet with our Mexican counterparts. The trip was part of a larger, proactive strategy to reach out to stakeholders, both domestic and foreign, to explain the background and implementation strategies for the new Food Safety Modernization Act (FSMA) and importantly, to listen to issues raised by stakeholders. Following Canada, Mexico is the largest exporter of foods to the United States. It was an exciting opportunity to meet with Mexican officials, not only to provide outreach on our new law, but also to gain a better understanding of Mexican food safety interests and challenges, and to identify areas for collaboration to further ensure the safety of foods for our respective populations.
Throughout the discussions, our team was impressed with the level of agreement on overarching principles and strategies to assure foods are safe for our respective populations. Like us, Mexico has embraced food safety as a priority and is in the process of establishing new mandatory food safety regulations, including produce safety regulations. Some of the key themes that were emphasized throughout our discussions were consumer protection, science- based standards, the need for importer controls, the importance and role of third- party certification. Throughout our discussions, I felt that I was indeed hearing many of the principles embodied in FSMA, such as the importance of prevention, the need to establish strong partnerships, a robust import program, and an effective program of risk-based inspections. In addition, there was a common recognition of the importance of making sure new regulations consider trade impacts, and the importance of transparency in rulemaking. Our strong alignment on key principles was both gratifying and extremely encouraging.
We had a whirlwind schedule. Highlights are as follows:
Our FDA delegation was welcomed to Mexico by Honorable John D. Feeley, U.S. Chargé d’Affaires to Mexico, and Mr. James H. Williams, Acting Deputy Chief of Mission, at the U.S. Embassy in Mexico City. The FDA delegation also met with representatives of U.S. agencies at the U.S. embassy in Mexico from Foreign Agricultural Services, Foreign Commercial Service, Animal and Plant Health Inspection Service; and the State Department Economic Section. Embassy officials were very helpful in sharing their perspectives on FSMA and potential cooperative activities with Mexico. Last year, FDA opened its new office in Mexico City. We were delighted to see our staff integrated into US Embassy activities and representing the agency in a stellar manner with our regulatory counterparts.
Next, we had an informative meeting with Mexican Government agencies involved in food safety. Mexican Government agencies represented included: Secretariat of Agriculture – Secretaría de Agricultura, Ganadería, Desarrollo Rural, Pesca y Alimentación / Servicio Nacional de Sanidad, Inocuidad y Calidad Agroalimentaria (SENASICA); Secretariat of Health – Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS); Secretariat of Economy – Secretaria de Economía; Secretariat of Foreign Affairs – Secretaria de Relaciones Exteriores; and Secretariat of the Environment- Ambiente y Recursos Naturales (which is the agency in charge of CONAGUA which plays an essential role in helping to ensure the quality of water used in farming and agriculture). Later in the day, we had a discussion with SENASICA to learn more and discuss their latest proposal for the revision of the FDA-SENASICA Cantaloupe MOU, which is scheduled to expire in October, 28, 2011. The parties agreed to further discuss possible opportunities for the enhancement of the MOU including possible enhanced collaboration on technical and operational protocols, exchange of regulatory information, as well as on food safety research.
We had the pleasure of having lunch with representatives of Mexican academic institutions including: National Autonomous University of Mexico (Universidad Nacional Autónoma de México); National Polytechnic Institute (National Instituto Politecnico); The Autonomous University of Puebla (Benemérita Universidad Autónoma de Puebla); and the Postgraduate College (Colegio de Postgraduados). The luncheon emphasized the important contribution of academia to the regulatory process on innovation and research, not only in food safety science but also in pubic health, political science, and business management.
One of the most dynamic parts of the day was a joint FDA, SENASICA and COFEPRIS roundtable with Mexican industry and trade organizations. Industry and trade expressed their concerns, views, and suggestions on FSMA. Participants discussed Mexico’s inspection protocols and FDA’s inspection procedures and import protocols at the border. We addressed questions related to produce safety preventive controls.
Following the meeting with industry, I participated in a press conference with senior officials from SENASICA and COFEPRIS and Mexican news media during which we were able to reinforce common messages on food safety.
We had a wonderful, productive day in Mexico. We acknowledged and indeed celebrated our common commitment to food safety.
Michael R. Taylor, Deputy Commissioner for Foods
Earlier this year, President Obama issued Executive Order (EO) 13563 and outlined his plan to create a 21st-century regulatory system that is simpler and smarter and that protects the health and safety of the American people in a pragmatic and cost-effective way. One goal of EO 13563 is to target rules already on the books to increase flexibility and remove regulations that are out-of-date, unnecessary, excessively burdensome, or in conflict with other rules.
On May 26, in support of EO 13563, more than two dozen Federal agencies released plans that identified initiatives with the potential to eliminate tens of millions of hours in reporting burdens, and billions of dollars in regulatory costs. FDA, as part of the Department of Health and Human Services (HHS), is included in the HHS Preliminary Plan for Retrospective Review of Existing Rules (HHS Plan), which can be seen at http://www.hhs.gov/open/recordsandreports/execorders/13563/draft/index.html. The HHS Plan identifies regulations already being modified or streamlined and identifies additional candidates for further review.
The HHS Plan highlights the activities FDA is undertaking in support of EO 13563. For example, we are reviewing the “Bar Code Rule” to assess the costs and benefits associated with it and to determine if the rule should be modified to take into account changes in technology that have occurred since the rule went into effect. The Bar Code Rule requires certain human drug and biological products to have a linear bar code on the label so health care professionals can use bar code scanning equipment to verify that the right drug (in the right dose and right route of administration) is being given to the right patient at the right time. Stay tuned for a solicitation of information on the Bar Code Rule. For further information about other FDA activities in support of EO 13563 see http://www.fda.gov/AboutFDA/Transparency/TransparencyInitiative/ucm257692.htm
As we go forward, we are very interested your input. As I wrote in our April 26 blog, at http://fdatransparencyblog.fda.gov/2011/04/26/what-needs-fixing-and-how-can-we-fix-it/, we do not operate in a vacuum and we value the input of all our stakeholders. On April 27, 2011, we published a notice in the Federal Register requesting comment and supporting data on which, if any, of our existing rules are outmoded, ineffective, insufficient or excessively burdensome and thus be candidates for review. Please review our Federal Register notice and the HHS plan and submit your comments to FDA by June 27, 2011 at http://www.regulations.gov/#!documentDetail;D=FDA-2011-N-0259-0001. You can also submit comment on the HHS plan at http://www.hhs.gov/open/recordsandreports/execorders/13563/draft/index.html
Leslie Kux, Assistant Commissioner for Policy (Acting)
Today, the FDA is implementing the first in a series of proposals to increase public understanding of the public health impact of FDA’s enforcement efforts, help inform companies’ efforts to comply with FDA requirements, increase company accountability to consumers and business partners, and help consumers make more informed decisions about the products they buy.
This action stems directly from the FDA Transparency Initiative, which Commissioner Margaret A. Hamburg, M.D. launched in 2009. The initiative is designed to examine all agency activities and consider ways to make them more transparent. After holding public meetings and inviting written comments, FDA issued its first report, proposing 21 actions to increase disclosures about agency activities. Today, the agency is taking several steps to increase transparency related to its enforcement activities:
• Posting a summary of the most common inspectional observations of objectionable conditions or practices that are made during inspections.
• Providing a searchable database that includes the name and address of inspected facilities, the date(s) of inspection, type of FDA-regulated products involved, and final inspectional classification.
• Alerting the public in a consistent manner about enforcement actions, by issuing press at the beginning and the end of the process, unless confidentiality is necessary.
The FDA is also providing a new web page to house all of the agency’s key transparency activities related to enforcement so that these resources will be easier to find and use.
In the coming months, 3 additional enforcement-related transparency actions will be implemented. FDA will begin to disclose additional information about FDA evaluations of importers, expand disclosure of Untitled Letters, and in appropriate situations, support industry efforts during a food recall to inform consumers of products that are not subject to the recall. FDA will also move forward on other proposals in the report.
The FDA doesn’t regulate in a vacuum. We need to listen to all our stakeholders – the American people who we protect and the industries we regulate. One important way we do this is by a process called retrospective review of regulations.
So what does this mean? As part of a process begun by President Obama, the FDA today announced that we are formally asking for submissions on how to improve existing regulations. Retrospective reviews like this really help us focus on how we can improve our regulations and give us invaluable insights on how we, and those we regulate, can be more innovative and take advantage of innovation as we work to protect and promote the public health.
For FDA, review of regulations is grounded in straightforward principles. First, regulations should change with the times. Second, they should not impede innovation and, if possible, foster it. Third, the effort they call for (the burden or cost of complying) should be reasonable. Fourth, they should not be ineffective. In other words, regulations should make sense, and if they don’t, we should change, strengthen, clarify, streamline, or revoke them.
That’s where you come in.
We want to hear from you. Help us identify areas to focus and improve. Where are our regulations ineffective? Do our regulations address current public health challenges? Where do we need to update our regulations? Can we revise them in ways that makes them less burdensome without making them less effective? Where can we be more flexible? How we can put greater emphasis on innovative scientific approaches? Do we have regulatory requirements that are redundant, inconsistent or needlessly overlap?
We’re most interested in big ideas, ones that identify regulatory problems that have the greatest impact on the public health.
If you want to help us with this important task, you can learn more by visiting the Federal eRulemaking Portal and following the instructions for submitting comments.
We are looking forward to your suggestions. Thank you very much – Leslie
Assistant Commissioner for Policy (Acting)
Today’s release of a strategic priorities document outlining the goals and strategies that the FDA and its 12,000 employees will pursue through 2015 marks a renewal of our commitment to creating a stronger, more effective agency.
Titled “Strategic Priorities 2011 – 2015: Responding to the Public Health Challenges of the 21st Century,” the 50-page document provides a vision of the FDA that includes:
- a modernized field of regulatory science that draws on innovations in science and technology to help ensure the safety and effectiveness of medical products throughout their life cycles
- an integrated global food safety system focused on prevention and improved nutrition
- expanded efforts to meet the needs of special populations.
Senior staff from the FDA’s seven product and research centers and two major offices contributed to the document. A Federal Register notice that invited public input in October 2010 generated more than 200 comments that were considered for the final document.
The field of regulatory science and innovation is among five cross-cutting areas that will serve as strategic priorities at the agency during the next five years.
The FDA must have the capacity to effectively oversee the translation of breakthrough discoveries in science into innovative, safe, and effective products and life-saving therapies. This document sets forth our priorities for achieving that goal.
Margaret A. Hamburg, M.D.
Commissioner of Food and Drugs
On April 4, 2011, FDA launched a new Web search to make it easier for consumers to search for food and other product recalls. The search results are in the form of a table that organizes information on recalls since 2009, by date, product name, product description, reason for recall, and recalling firm. The table also provides a link to the news release for each recall. This new display of recall information differs from the old display, which provided links in a scroll-down format. Before launching the new search function, FDA consulted with a range of interested stakeholders on how to communicate recall information most effectively. FDA believes the new display of search results will be much easier for consumers to use. Here is a link to the news release announcing the new Web search: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm249437.htm
and a link to the search Web page: http://www.fda.gov/Safety/Recalls/default.htm.